NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
Last week the Nordic healthcare stocks rose 0.6%, while the Danish healthcare stocks rose 8%. CS Medica is evaluating a potential spin-off of CANNORDIC, Goldman Sachs increased its price target of Genmab, and Pila Pharma completed a directed share issue as well as an agreement with Lindus Health. The Danish healthcare stocks have on average increased 46% year-to-date.
11 of the 22 Danish healthcare companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 415% return and CS Medica was the best Nordic healthcare investment last week. 5 Danish healthcare stocks with +100% YTD return.
Danish company news
No news the past week
No news the past week
No news the past week
Grant of incentive warrants to Employees, CEO and the Board of Directors (Link)
CS MEDICA A/S Evaluates Pre-IPO Share Distribution for CANNORDIC Stock Spin-off (Link)
CS MEDICA Receives “Intention To Grant” for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Goldman Sachs increased its target price from DKK 2242 to DKK 2378
No news the past week
No news the past week
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (Link)
Pila Pharma’s board of directors announces completion of a fully subscribed directed issue of approximately SEK 10 million (Link)
Pila Pharma inks agreement with Lindus Health about next clinical trial with safety and obesity readouts (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a very strong share price performance the past week with an 8% increase compared to the 0.6% for the KPHC index. CS Medica became the by far best-performing stock with a 158% increase. The company is currently evaluating an IPO share distribution of subsidiary CANNORDIC along with other patent news. However, the stock rose significantly prior to the news of the spin-off and patent news. Genmab rose 4% following an increased price target from Goldman Sachs, and Pila Pharma completed a SEK 10 million directed share issue and signed an agreement with Lindus Health about its next clinical trial with safety and obesity readouts.
The best stock year-to-date is Gubra followed by Pila Pharma with 415% and 262% increases after the first 6 months of trading. CS Medica, Zealand Pharma, and Acarix have also made a +138-218% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 46%. In other words, it has had a stellar performance.
Overview of share price development the past week, year-to-date, and the last twelve months
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 0.6% to 70.91. The index has had a strong performance since the end of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 5-8%.
The index development for the KPHC index the past year
158-34% in weekly return for the Nordic healthcare stocks
CS Medica (158%) is a Danish medical device company, dedicated to pharmaceutical research, development, manufacturing, and global commercialization. The company blends science and nature to improve patients’ lives with cannabinoid therapies for pain relief, and to manage autoimmune and stress-related symptoms. Globally, CS Medica offers CBD treatments over-the-counter (OTC), including patented medical products, MHRA, and MDR-registered items, under the CANNASEN® brand or with private labeling.
Arcede Pharma (94%) is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company’s product portfolio includes drugs intended for the treatment and relief of the above conditions. Most of its activities are in the Nordic market.
Saniona (34%) is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company’s product portfolio includes drugs intended for the treatment and relief of the above conditions. Most of its activities are in the Nordic market.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
